At 50 days following initial treatment, overall survival was significantly extended in mice that received IL-15 complex alone, anti-PD-1mAb alone, or the combined treatment of IL-15 complex plus anti-PD-1 compared to vehicle control mice (0/12 mice tumor-free) (Figure 1F). Here, IL15 is linked to neoplasm.